Targeting Nitric Oxide: Say NO to Metastasis

Area of Science:

• Oncology
• Cancer Research
• Molecular Biology

Background:

• Minimizing cancer mortality requires targeted therapies against metastasis, chemoresistance, and cancer stem cells.
• Nitric oxide synthase (NOS) in the tumor microenvironment is a key target for reducing metastasis and enhancing chemo/radiotherapy.
• Nitric oxide (NO) plays a significant role in tumor progression and metastasis.

Approach:

• This review synthesizes preclinical findings on NOS inhibitors as anticancer agents.
• It examines the influence of nitric oxide (NO) on tumor progression and metastasis.
• The review discusses the prospects and challenges of clinical applications of NOS inhibitors.

Key Points:

• Targeting NOS can inhibit cancer metastasis and overcome chemoresistance.
• NOS inhibitors show promise in preclinical studies for various solid malignancies.
• Understanding NO's role in the tumor microenvironment is crucial for developing effective therapies.

Conclusions:

• NOS inhibitors represent a promising therapeutic avenue for cancer treatment.
• Further research is needed to address the challenges for clinical translation.
• Targeting NOS offers a strategy to improve outcomes in solid tumors by reducing metastasis and enhancing conventional therapies.